Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

Haematologica

Volumn 100, Issue 6, 2015, Pages e237-e239

  Winkelmann, Nils ^a,b   Rose Zerilli, Matthew ^c   Forster, Jade ^c   Parry, Marina ^c   Parker, Anton ^c,d   Gardine, Anne ^d   Davies, Zadie ^d   Steele, Andrew J ^c   Parker, Helen ^c   Cross, Nicholas C P ^a,c   Oscier, David G ^c,d   Strefford, Jonathan C ^c  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Early stage chronic lymphocytic leukemia; Low frequency mutations; Monoclonal B cell lymphocytosis; Treatment free survival

Indexed keywords

BIRC3 PROTEIN; EXPORTIN 1; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; POT1 PROTEIN; PROTEIN; SF3B1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL B CELL LYMPHOCYTOSIS; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; AGED; B LYMPHOCYTE; COHORT ANALYSIS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; MORTALITY; MUTATION; PATHOLOGY; PREDICTIVE VALUE; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

AGED; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; MALE; MUTATION; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84930510628     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.120238     Document Type: Article

References (9)

1. Strefford JC. The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol. 2015; 169(1):14-31.
2. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014; 28(1):108-117.
3. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
4. Oscier DG, Rose-Zerilli MJJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;120(22):4441-4443.
5. Ramsay AJ, Quesada V, Foronda M, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet. 2013;45(5):526-530.
6. Ojha J, Secreto C, Rabe K, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014;28(12):2395-2398.
7. Martínez-Trillos A, Pinyol M, Navarro A, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014; 123(24):3790-3796.
8. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015; 29(2):329-336.
9. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23(1):212-214.